-
Uncategorized8 hours agoSTAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to...
-
Uncategorized9 hours ago
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
-
Uncategorized9 hours ago
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
UniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge...
-
Uncategorized9 hours agoFederal government could improve infectious disease monitoring, says federal government
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. What dish will health secretary Robert F. Kennedy...
-
Uncategorized13 hours agoOpinion: What a recent op-ed got wrong about our Covid study
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and...
-
Uncategorized22 hours ago
Spatiotemporal Multiomics Charts Cellular Dynamics of Liver Metastasis
Metastasis remains one of cancer’s most difficult biological transitions to capture: tumor cells must leave a primary tumor, survive circulation, enter a distant organ, and then...
-
Uncategorized23 hours ago
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers...
-
Uncategorized1 day agoReplimune melanoma drug wins support of FDA panel
The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.
-
Uncategorized1 day agoAlnylam plunges as earnings deliver ‘one-two punch’
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business. Read...
-
Uncategorized1 day agoCapricor’s data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies?...
Capricor CEO won’t rule out legal action against FDA after negative adcomm
Ketamine Triggers Sex-Specific Brain Recovery Responses
